Amazon and Novartis team up on cloud services

pharmafile | December 5, 2019 | News story | Sales and Marketing Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines 

Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul Novartis’s manufacturing, supply and business operations.

Amazon Web Services announced that its technology would “help drive agility, innovation and cost efficiencies across Novartis global business processes and systems.”

Together they will create Insight Centers, which will provide real time data about the company’s distribution and manufacturing operations. It will also allow them to forecast and track production lines, detect potential bottlenecks and make adjustments to avoid them.

Betrand Bodson, the Chief Digital Officer of Novartis, said in a statement: “There is a lot we can learn from the Amazon Web Services team, and while manufacturing is a great starting place, we’re keen to also explore where else we can apply this technology. Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster.”

Novartis has already adopted Amazon’s computer products, using their computer vision equipment to check over their manufacturing lines.

The companies have already begun working on implementing the cloud computing technology, with the first demos to be ready by the end of the year.

This collaboration follows Novartis announcing a partnership with Microsoft back in October, to bring AI tools to every desk across its R&D departments.

Conor Kavanagh

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content